Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Safaee, Michael ^a   Clark, Aaron J ^a   Oh, Michael C ^a   Ivan, Michael E ^a   Bloch, Orin ^a   Kaur, Gurvinder ^a   Sun, Matthew Z ^a   Kim, Joseph M ^a   Oh, Taemin ^a   Berger, Mitchel S ^a   Parsa, Andrew T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD97 ANTIGEN; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; SEQUENCE ANALYSIS; SURVIVAL RATE; TUMOR INVASION;

ANTIGENS, CD; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; PHENOTYPE; PRIMARY CELL CULTURE; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS;

EID: 84876869343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062765     Document Type: Article

References (48)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, et al. (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99: 467-473.
3. Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, et al. (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102: 622-628.
4. Yona S, Lin HH, Siu WO, Gordon S, Stacey M, (2008) Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33: 491-500.
5. Hamann J, Eichler W, Hamann D, Kerstens HM, Poddighe PJ, et al. (1995) Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J Immunol 155: 1942-1950.
6. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, et al. (1996) CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157: 5438-5447.
7. Lin HH, Stacey M, Hamann J, Gordon S, McKnight AJ, (2000) Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 67: 188-200.
8. Stacey M, Lin HH, Hilyard KL, Gordon S, McKnight AJ, (2001) Human epidermal growth factor (EGF) module-containing mucin-like hormone receptor 3 is a new member of the EGF-TM7 family that recognizes a ligand on human macrophages and activated neutrophils. J Biol Chem 276: 18863-18870.
9. Caminschi I, Lucas KM, O'Keeffe MA, Hochrein H, Laabi Y, et al. (2001) Molecular cloning of F4/80-like-receptor, a seven-span membrane protein expressed differentially by dendritic cell and monocyte-macrophage subpopulations. J Immunol 167: 3570-3576.
10. Stacey M, Chang GW, Sanos SL, Chittenden LR, Stubbs L, et al. (2002) EMR4, a novel epidermal growth factor (EGF)-TM7 molecule up-regulated in activated mouse macrophages, binds to a putative cellular ligand on B lymphoma cell line A20. J Biol Chem 277: 29283-29293.
11. Nechiporuk T, Urness LD, Keating MT, (2001) ETL, a novel seven-transmembrane receptor that is developmentally regulated in the heart. ETL is a member of the secretin family and belongs to the epidermal growth factor-seven-transmembrane subfamily. J Biol Chem 276: 4150-4157.
12. Eichler W, Hamann J, Aust G, (1997) Expression characteristics of the human CD97 antigen. Tissue Antigens 50: 429-438.
13. Hamann J, Vogel B, van Schijndel GM, van Lier RA, (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184: 1185-1189.
14. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, et al. (2003) The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102: 2916-2924.
15. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, et al. (1998) Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28: 1701-1707.
16. Qian YM, Haino M, Kelly K, Song WC, (1999) Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98: 303-311.
17. Wang T, Ward Y, Tian L, Lake R, Guedez L, et al. (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105: 2836-2844.
18. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, et al. (2011) Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res 71: 6371-6381.
19. Friedlander DR, Zagzag D, Shiff B, Cohen H, Allen JC, et al. (1996) Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 56: 1939-1947.
20. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, et al. (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51: 4986-4993.
21. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, et al. (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161: 1657-1667.
22. Holting T, Siperstein AE, Clark OH, Duh QY, (1995) Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132: 229-235.
23. Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, et al. (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 118: 699-707.
24. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, et al. (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798-1806.
25. Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, et al. (2006) Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol 169: 1802-1811.
26. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI, Broaddus WC, (2012) Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116: 843-853.
27. Rutkowski MJ, Sughrue ME, Kane AJ, Kim JM, Bloch O, et al. (2011) Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. J Neurooncol 105: 165-171.
28. Kane AJ, Sughrue ME, Rutkowski MJ, Phillips JJ, Parsa AT, (2010) EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target. Neuroreport 21: 1018-1022.
29. Voris HC, (1934) Tumors of the frontal lobe of the brain: anatomic, pathologic and clinical analysis. Proc Mayo Clin 9: 396-399.
30. Matsukado Y, Maccarty CS, Kernohan JW, (1961) The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 18: 636-644.
31. Becker S, Wandel E, Wobus M, Schneider R, Amasheh S, et al. (2010) Overexpression of CD97 in intestinal epithelial cells of transgenic mice attenuates colitis by strengthening adherens junctions. PLoS One 5: e8507.
32. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, et al. (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res 71: 7301-7311.
33. Lin ME, Herr DR, Chun J, (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130-138.
34. Mahesparan R, Tysnes BB, Read TA, Enger PO, Bjerkvig R, et al. (1999) Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro. Acta Neuropathol 97: 231-239.
35. Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K, (1998) Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18: 2599-2605.
36. Rooprai HK, Vanmeter T, Panou C, Schnull S, Trillo-Pazos G, et al. (1999) The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci 17: 613-623.
37. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, et al. (2010) alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 127: 1240-1248.
38. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, et al. (2012) Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106: 147-153.
39. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, et al. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689.
40. Anand M, Van Meter TE, Fillmore HL, (2011) Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J Neurooncol 104: 679-687.
41. Tonn JC, Goldbrunner R (2003) Mechanisms of glioma cell invasion. Acta Neurochir Suppl 88: 163-167.
42. Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, et al. (1999) Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5: 845-854.
43. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, et al. (2006) Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78: 295-302.
44. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, et al. (2002) Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20: 1383-1388.
45. Kop EN, Adriaansen J, Smeets TJ, Vervoordeldonk MJ, van Lier RA, et al. (2006) CD97 neutralisation increases resistance to collagen-induced arthritis in mice. Arthritis Res Ther 8: R155.
46. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, et al. (2005) Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15: 222-231.
47. Mustafa T, Eckert A, Klonisch T, Kehlen A, Maurer P, et al. (2005) Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 14: 108-119.
48. Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, et al. (1999) Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 84: 1104-1109.